Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Not recommended Other
prevention of human papillomavirus (HPV) in males 12-13 years of age and a catch-up program over 2 years for Year 9 males
3
Submissions
2 resub
2006–11
On the record
$15k–70k
ICER range
3 sourced ICERs · 2006–2011
ICER stated
Cost basis
Decision on record
- Meeting Nov 2006 Not recommended Vaccine no PSD
Access path
- Nov 2006Recommended · restricted
vs Standard medical management, including the National…
- Mar 2011Recommended · restricted
ICER dropped $70,000 → $45,000 (-36%)
- Nov 2011Recommended · restricted
Comparator changed: no vaccination (placebo); secondary comparator: female-only…
- PBS listing
RecommendedDeferredNot recommended
Cost-effectiveness
Base case ICER stated as a band. ICER increases to $45,000–$75,000/QALY when no growth of anal and oropharyngeal cancer is assumed after 2014.
The PBAC observed that all the clinical uncertainties flowed into the modelled economic evaluation, but that the sensitivity analyses provided did not permit a full assessment of the impact of the clinical uncertainties. PBAC · 2011
ICER uncertainEconomic model disputed
Decision context
Populationmales aged 12-13 years and Year 9 males (catch-up program)
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2011 | Recommended · restricted | current female HPV vaccination | $15k–45k | RCT |
| Mar 2011 | Recommended · restricted | no vaccination (placebo); secondary comparator: female-only vaccination | $15k–45k | RCT |
| Nov 2006 | Recommended · restricted | Standard medical management, including the National Cervical Screening Program (NCSP) | $15k–70k | RCT |
Similar precedents
Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine89%Human Papillomavirus 9-Valent Vaccine81%Human Papillomavirus (Types 16 And 18) Recombinant, As04 Adjuvanted Vaccine76%Human Papillomavirus (Hpv) Types 16/18 Vaccine72%Human Rotavirus Vaccine61%Zoster Virus Vaccine Live (Oka/Merk)59%Meningococcal Polysaccharide Conjugate Vaccine Serogroups A, C, W-135 And Y58%Hepatitis B Surface Antigen Recombinant Vaccine58%